| Document |
Document Title |
|
WO/2023/205857A1 |
The present disclosure relates to a novel compound, which is an analogue of vitamin D. The present disclosure also relates to pharmaceutical compositions including the novel compound, and to the use of the novel compound in treating and/...
|
|
WO/2023/196668A2 |
Embodiments include prodrug compounds, that can be used, inter alia, for treating an ailment such as cancer. The prodrug compounds can include an active agent component such as a cyclic monoterpene. The compounds can also include a prodr...
|
|
WO/2023/155000A1 |
The present invention provides a high-throughput screening method for vitamin D determination in a biological sample by using direct infusion-tandem mass spectrometry (DI- MS/MS). The method comprises subjecting the biological sample to ...
|
|
WO/2023/115220A1 |
A combination comprising tilorone/nelfinavir; tilorone/molnupinavir; tilorone/remdesivir; tilorone/alfacalcidol; tilorone/clofazimine; tilorone/danazol; tilorone/manidipine; tilorone/sertraline; tilorone/trifluoperazine; remdesivir/hexac...
|
|
WO/2023/068322A1 |
Provided is a new vitamin D derivative that is useful for preventing or treating cancer or psoriasis. The vitamin D derivative is a compound represented by general formula (I) (in the formula, X represents a linear or branched alkyl grou...
|
|
WO/2023/000135A1 |
Provided are new process and intermediates for preparing onapristone.
|
|
WO/2022/126255A1 |
The present invention provides methods and compositions for immune support of immune function. The compositions comprise vitamin C; zinc; vitamin D3; elderberry fruit extract; ginger root extract; and at least one excipient. The composit...
|
|
WO/2022/061193A1 |
Provided are vitamin D3 derivatives of formula (I), pharmaceutical compositions thereof, and pharmaceutical or medical uses thereof for treating metabolic disease, a liver disease, obesity, diabetes, cardiovascular disease, or cancer in ...
|
|
WO/2021/105147A1 |
It is provided a cocrystal of a compound of formula (I) or of a compound formula (II) wherein X and Y are independently selected from -CH2- and -C(CH2)-, provided that al least one of X or Y is -CH2-; R1 is -CHCH3-Zm-Wn-(CH2)o-Tp-S, wher...
|
|
WO/2021/053239A1 |
The present invention concerns a process for producing formic acid, comprising (a) a carbon capture step wherein a source of carbon dioxide is contacted with an amine solution in a closed- top scrubber, to obtain an ammonium bicarbonate ...
|
|
WO/2021/053244A1 |
The present invention concerns a process for producing formic acid, comprising (a) a carbon capture step wherein a source of carbon dioxide is contacted with an amine solution in an amine scrubber, to obtain an ammonium bicarbonate solut...
|
|
WO/2021/005619A1 |
Disclosed herein is an improved and efficient process for synthesis of vitamin D3 and its analogue Calcifediol from Ergosterol. Particularly, the present invention discloses the synthesis of key intermediate 3β-tert-Butyldimethylsilylox...
|
|
WO/2021/005618A1 |
The present invention discloses novel method for synthesizing vegan cholesterol and vitamin D3 from inexpensive crude phytosterol.
|
|
WO/2020/236722A1 |
Compositions and methods for treating obesity are provided. In certain embodiments, the compositions comprise the topical vitamin D3 derivative MC903. In other embodiments, the compositions systemically increase TSLP levels in a subject....
|
|
WO/2020/230159A1 |
The invention discloses an improved process for production of vitamin D3 from 7- dehydrocholesterol (7- DHC) and to a simple process for recovery unreacted 7-DHC for further reuse. The invention further describes a process for isolation ...
|
|
WO/2020/230169A1 |
The present invention discloses an improved photochemical synthesis of vitamin D3 from 7-dehydrocholesterol alone or in combination with sterol precursors in presence of the photosensitizer of Formula I in high yield and with reduced lev...
|
|
WO/2020/119163A1 |
Disclosed is a method for preparing a mushroom vitamin D 2 oil, the method comprising: slicing a mushroom raw material and then treating same with ultraviolet irradiation that is a combination of UVB irradiation at 280-315 nm and UVC irr...
|
|
WO/2020/014776A1 |
An oral dispersible film composition comprising at least one active ingredient and a film forming agent, as well as a method of manufacture of same. The oral dispersible film composition can be free of gum resin, and can be utilized to a...
|
|
WO/2019/232095A1 |
Disclosed are cationic lipids comprising a vitamin substructure and an ionizable nitrogen- containing group. Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of l...
|
|
WO/2019/201569A1 |
A process for preparing dialkyl terephalate comprising the following steps:- i) providing furan-2,5-dicarboxylate; ii) esterifying the furan-2,5-dicarboxylate with alcohol to form furan-2,5-carboxylic acid dialkyl ester; iii) reacting th...
|
|
WO/2019/154237A1 |
The present invention relates to a co-crystal of calcifediol and vitamin D3, a preparation method therefor and use thereof. In the co-crystal, the molar ratio of calcifediol to vitamin D3 is 1: 1. The co-crystal of calcifediol and vitami...
|
|
WO/2019/153673A1 |
The present invention provides a 25-hydroxycholecalciferol monohydrate crystal and a preparation method therefor, and a microemulsion using the 25-hydroxycholecalciferol monohydrate crystal. The X-ray powder diffraction spectrum of the 2...
|
|
WO/2019/106214A1 |
The present invention relates to compounds derived from vitamin D. More particularly, it relates to complex vitamin D derivatives with multiple substitutions, to production methods and to uses of same. These derivatives show greater rigi...
|
|
WO/2019/079279A1 |
Disclosed are methods of purifying the compound (22E)-(247R)-2-methylene- 22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving (22E)-(24R)-2-m...
|
|
WO/2019/052470A1 |
Disclosed are an eldecalcitol crystal form, a pharmaceutical composition and a preparation method and the use. The eldecalcitol crystal form has characteristic peaks at the diffraction angle 2θ = 5.2° ± 0.2°, 10.4° ± 0.2°, 15.6° ...
|
|
WO/2019/040879A1 |
Disclosed herein are methods of using immunomodulatory sterols as vaccine adjuvants. Accordingly, certain embodiments relates to pharmaceutical compositions containing at least one antigen and at least one immunomodulatory sterol; and, m...
|
|
WO/2018/175186A1 |
Described herein are methods for measuring analytes, wherein a portion of the analyte in a sample is bound by a binding protein. In some embodiments, the methods relate to measuring vitamin D or metabolites thereof, e.g., vitamin D in sa...
|
|
WO/2018/130865A1 |
A composition for treating headaches and migraines and methods of using same for preventative use to decrease the frequency, duration and severity of headaches and migraines in children and adults.
|
|
WO/2018/026781A1 |
Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/...
|
|
WO/2017/127833A1 |
The present invention provides methods, devices, and compositions to rapidly detect analytes, including small analytes, using a lateral flow device. Described herein is such a lateral flow device that can detect and quantify vitamin D in...
|
|
WO/2017/053793A1 |
Methods and systems for making intermediates in the synthesis of onapristone are provided. Aspects include the photoconversion of onapristone synthesis intermediates using a narrow band frequency light source.
|
|
WO/2017/023617A1 |
Disclosed are 2-methylene analogs of vitamin D3 and related compounds, their biological activities, and various pharmaceutical uses for these analogs. Particularly disclosed are 1α-hydroxy-2-methylene-vitamin D3, (20S)-1α-hydroxy-2-met...
|
|
WO/2017/014332A1 |
The present invention provides a novel drug delivery conjugated moiety for oral administration of a drug that is not suitable for oral administration or a pharmaceutically acceptable salt thereof. When the drug delivery conjugated moiety...
|
|
WO/2016/192564A1 |
Disclosed are a polyene compound, preparation method and use thereof. Provided in the present invention is the preparation method of a polyene compound I, comprising the following steps: under an action of a base and in an organic solven...
|
|
WO/2016/191583A1 |
Disclosed are la,25-dihydroxy-24,24-difluoro-2-methylene-19-nor- vitamin D analogs of formula I and their pharmaceutical uses. These new vitamin D analogs are 19-nor-vitamin D analogs having two fluorine atom substitutions at the 24 posi...
|
|
WO/2016/103722A1 |
The present invention relates to vitamin D3 derivatives of the following formula, wherein each symbol has the same meaning as defined herein, and pharmaceutical or medical use thereof for treating metabolic disease, liver disease, obesit...
|
|
WO/2016/100892A1 |
It is an object of the present invention to provide methods for producing vitamin D that gives improved yields and reduced side product contamination. In various aspects, these methods provide for production of vitamin-D2 using ergostero...
|
|
WO/2016/058472A1 |
Provided are a vitamin D2 and vitamin D3 eutectic crystal, a preparation method and use thereof, and a pharmaceutical composition comprising the eutectic crystal. The vitamin D2 and vitamin D3 eutectic crystal has the advantages of a hig...
|
|
WO/2016/056610A1 |
The present invention provides a method for manufacturing 7-dehydrocholesterol (7-DHC), the method being characterized by culturing, in a culture medium, a labyrinthulean micro-organism that produces 7-DHC and that has decreased sterol 2...
|
|
WO/2015/108058A1 |
The present invention provides a method for manufacturing 7-dehydrocholesterol, the method being characterized by deleting, replacing or adding at least one base in a gene that is present on the chromosomal DNA in a parent strain and tha...
|
|
WO/2015/098152A1 |
The present invention is a method that is for preparing a crystallography sample for determining the molecular structure of a metabolite and that is characterized by having a step in which, by means of contacting, to a solvent solution c...
|
|
WO/2015/018757A1 |
The present invention relates to novel vitamin D compounds bonded to a marker group via a linker at the C-3 stereocenter. The present invention further relates to a process for preparing these vitamin D compounds and to the use of an int...
|
|
WO/2014/165232A1 |
The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of cancer.
|
|
WO/2014/116386A1 |
Disclosed are (22E)-2-methylene-22-dehydro-1,24,25-trihydroxy-19-nor-vitam
in D3 compounds, their biological activities, and various pharmaceutical uses for these compounds. Particularly disclosed are (22E )-(24R)-2-methylene-22-dehydro-...
|
|
WO/2014/091046A1 |
Versatile and functionalised intermediates for the synthesis of vitamin D and novel vitamin D derivatives. The invention provides novel intermediates for the complete synthesis of vitamin D and allows a great versatility of functional gr...
|
|
WO/2014/024210A2 |
The present invention provides a novel amorphous Form of doxercalciferol, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides a solid dispersion of doxercalciferol in combination...
|
|
WO/2013/184412A1 |
Disclosed are 19-nor-vitami D compounds, and specifically seco-A-2, 19-dinor- 1,25- dihydroxyvitamin D3 as well as pharmaceutical uses therefor. These compounds exhibit relatively high activity in vivo, specifically in intestinal tissues...
|
|
WO/2013/180882A1 |
Disclosed are methods of purifying the compound (20R)-19-nor-24- difluoro-1α,25-dihydroxyvitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving a product containing the compound in a...
|
|
WO/2013/180880A1 |
Disclosed are methods of purifying the compound (20R>2-methylene-19-nor-24- difluoro-1α,25-dihydroxy vitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving a product containing the c...
|
|
WO/2013/180879A1 |
Disclosed are methods of purifying (20R) and (20S) analogs of 2-methylene-19- nor-22-dimethyl-1α,25-dihydroxyvitamin D3 to obtain the (20R) and (20S) analogs in crystalline form. The method includes the steps of preparing a solvent of e...
|
